The third patient of Elon Musk's brain computer interface company Neuralink is using the billionaire's foul-mouthed AI ...

The approved ALS therapy Radicava may cause serious unexpected side effects, such as liver problems and blood clots, per U.S.

Clene’s cash and cash equivalents totaled $9.8 million as of March 31, 2025, compared to $12.2 million as of December 31, 2024. Clene expects that its resources as of March 31, 2025, will be ...

Prilenia, Ferrer entered collaboration agreement for commercialization and co-development of pridopidine in Europe and other ...

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Houston mortgage duo Cissy and Christopher Larkin are channeling a four-year ALS battle into a widespread fundraiser.

Eli Lilly (LLY) inks a licensing agreement with Alchemab to jointly develop an ALS drug in a $415M deal. Read more here.

Alchemab Therapeutics Ltd. has entered into a licensing agreement with Eli Lilly and Co. for ATLX-1282, Alchemab’s first-in-class IND-ready program targeting a novel receptor and mechanism for ...

In the summer of 2015, the Ice Bucket Challenge stormed the internet. Social media was flooded with videos of people dumping ...

Amyotrophic lateral sclerosis (ALS)—known as Lou Gehrig's Disease, based on the iconic 1930s New York Yankee baseball ...

ALS patient Bradford Smith became the third patient to test Neuralink — and the first one to do so who had lost the ability ...